Markets

Latest News

Actelis Networks Accelerates Growth with New Italian Transportation Order Expansion, Strengthening Momentum in Road Safety and ITS
Technology

Actelis Networks Accelerates Growth with New Italian Transportation Order Expansion, Strengthening Momentum in Road Safety and ITS

Actelis Networks has recently expanded its presence in the intelligent transportation systems (ITS) and road safety sectors, underscoring its position as a global leader in cyber-hardened networking solutions. This growth was highlighted by a new order for its temperature-hardened hybrid-fiber technology from a major Italian motorways operator,

World & Politics

Tensions Explode: U.S. Warns Iran After Massive Missile Attack on Israel

The United States has issued a stern warning to Iran following its recent missile attack on Israel, promising “severe consequences” for the escalation of hostilities. On Tuesday, Iran launched a massive ballistic missile strike against Israel, with the Israel Defense Forces reporting that approximately 180 missiles were fired. The majority

World & Politics

Power Play: Olivia Nuzzi Files Restraining Order Against Ex-Fiancé Ryan Lizza Amid Explosive Allegations of Bla ckmail and Surveillance

New York magazine political reporter Olivia Nuzzi has filed for a civil protection order against her former fiancé, Politico journalist Ryan Lizza, alleging blackmail and threats to her career. The court documents, reviewed by Business Insider, reveal a complex situation unfolding amid scrutiny of Nuzzi’s relationship with presidential candidate

Silexion Therapeutics Announces Additional Preclinical Success with SIL-204; Plans to Initiate Pre Clinical Trials for Colorectal Cancer
Health & Pharma

Silexion Therapeutics Announces Additional Preclinical Success with SIL-204; Plans to Initiate Pre Clinical Trials for Colorectal Cancer

Silexion Therapeutics (NASDAQ: SLXN) has reported promising preclinical data for SIL-204, its next-generation siRNA candidate targeting KRAS mutations in pancreatic cancer. This announcement comes just days after the company revealed strong results from its Phase 2 trial of LODER™, another RNAi-based therapy designed for pancreatic cancer treatment.

Business & Deals

A New Dawn: Indian Expatriates Fueling the Startup Revolution Back Home

In recent years, a growing number of Indian expatriates are choosing to leave lucrative positions at major technology companies in Silicon Valley and return to their homeland to launch their own startups. This reverse migration trend is being driven by several factors, including India’s booming economy, expanding internet adoption,